Clinical trials in Do Not Edit

Researchers in Do Not Edit are evaluating long‑term outcomes for patients with ANCA-associated vasculitis by comparing relapse rates after stopping versus maintaining rituximab therapy.

• ANCA-associated vasculitis
• Rituximab maintenance vs discontinuation
• Relapse rate as primary endpoint
• Stable remission cohort

The trial aims to inform optimal treatment duration and improve quality of life for individuals living with this autoimmune condition.

Although current recruiting studies focus on immune and oncologic conditions, the local research community is preparing protocols to address musculoskeletal disorders such as inflammatory arthritis and osteoporosis.

• Potential focus on rheumatoid arthritis
• Exploration of biologic therapies
• Patient‑reported outcome measures
• Collaboration with orthopedic centers

Future investigations are expected to expand the therapeutic portfolio and offer new options for bone and joint health in the region.

An ambitious trial in Do Not Edit compares a novel combination of pirtobrutinib and epcoritamab against standard R-(mini)-CHOP for individuals with Richter transformation arising from CLL or DLBCL.

• Richter transformation in untreated patients
• Targeted BTK inhibition with pirtobrutinib
• Bispecific antibody epcoritamab
• Standard chemo‑immunotherapy comparator

The study seeks to improve response rates and durability of remission for this aggressive lymphoma subtype.